Healthcare Industry News: Cardiovascular Systems Inc
News Release - January 11, 2017
US Endovascular Announces John F. Vacha & Paul A. Tyska Join The Partnership
ST. LOUIS, Jan. 10, 2017 -- (Healthcare Sales & Marketing Network) -- US Endovascular, a Midwest based medical device company focused on the needs of healthcare providers, today announced that, effective January 1, 2016, John F. Vacha, CPA and Paul A. Tyska have joined as partners in the Company.Mr. Vacha is the former CEO of Intact Medical Corporation, a medical device company acquired by Medtronic. Prior to taking over as CEO, Mr. Vacha was the CFO of Intact Medical and brings 18 years of medical device management experience to US Endovascular and will take on the role of Chief Operating Officer & Chief Financial Officer.
Mr. Tyska is a senior level executive with proven success in defining and executing strategies to take medical/surgical device companies from Pre-FDA approval through market commercialization to rapid annualized revenue growth. Mr. Tyska brings over 27 years of experience, most recently as the Director of Market Development of Cardiovascular Systems Inc, a publicly traded medical device company. Mr. Tyska will work to expand the outreach of the current product portfolio in the rapidly growing Office Based Labs (OBL) market as well as asses' new technology.
Commenting on today's news, John McCurdy, CEO of US Endovascular noted, "We are pleased to welcome both John & Paul as partners in US Endovascular. As one of the first employees of Intact Medical, John helped develop the infrastructure of the business and lead it to a successful exit via M&A. His experience in leadership, finance and operations will add depth to the team. We are also excited with Paul joining as a partner as well. Paul's extensive experience in sales, market development, strategic planning and new opportunity evaluation will assist in expanding the outreach of our current product portfolio as well as provide additional bandwidth to assess new opportunities that can add value to our customers.
About US Endovascular
US Endovascular is a Midwest based medical device company established in 2014 to address the needs of healthcare providers in this dynamic market. The US Endovascular team, with over 70 years of combined experience, recognizes the traditional relationship between device company/manufacturer & healthcare provider must change in order to reduce costs.
The fundamental premise of US Endovascular is to obtain next-generation clinically-relevant devices from manufacturers on an exclusive basis, and provide them directly to the end user, economic buyer or corporate partner. This approach substantially reduces costs by eliminating unnecessary layers and processes.
The Company's streamlined and efficient sales and marketing approach positions them to rapidly gain market share in today's complex demanding environment. Converging market forces within healthcare, consolidation and the demand for high quality at low cost aligns with the company's low overhead distribution model (traditional SG&A costs removed). By focusing on relationships with large healthcare providers & delivery networks, aligning with complimentary device companies, and partnering with a world-class logistics organization, USE can maximize efficiencies and optimize value.
A developing portfolio of high quality complimentary products, specifically coronary and peripheral angioplasty balloons, coronary and peripheral wires and robust pipeline of next generation technology provides USE with the unique ability to highlight line-by-line savings, bundle and restrain competitors. Clinical support and product implementation teams dedicated to providing solutions are fundamental to the strategy.
USE is ideally positioned to leverage its superior sales channels, streamline the sales/distribution process and change the paradigm.
For more information on US Endovascular, visit www.usendovascular.net
Source: US Endovascular
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
